25th AGAH Annual Meeting 2016
Annual Meeting 2016, Berlin
The immune system is an important target in medicines development. Effective drugs against cancer, viral and bacterial infections or autoimmune diseases have entered the clinic; immunotherapy of cancer was even claimed to be the imminent breakthrough of the year in 2013.
Immunotherapy is the main topic of the upcoming annual meeting of the AGAH. The conference will start with an overview about how to define different approaches and will present an insight into current and future therapeutic opportunities. With respect to early medicines development, the conference will focus on special requirements regarding the development of medicines in this field.
The annual congress offers a one-day pre-meeting workshop about the basics of immunology. This workshop will be held by experts and is designed to teach the basic principles and functions of the immune system starting from scratch. The workshop is the ideal preparation for the annual meeting for those who are not yet experts in the field.
As this is the 25th anniversary of the AGAH we are looking forward to celebrating this event with you and are happy to welcome you to Berlin.
The Board of the AGAH e.V.
Exploratory drug development in immunological therapy – from in vitro pharmacology to early patient trials
Kaiserin Friedrich Haus
Robert-Koch-Platz 7
10115 Berlin
Phone: 030 / 30888928
Wednesday, 20th April 2016 (General Assembly)
Thursday, 21st April 2016
Friday, 22nd April 2016
CSi Hamburg GmbH
Jungfrauenthal 22, D-20149 Hamburg
Phone: +49 40 30770 300
Fax: +49 40 30770 301
E-Mail: agah-veranstaltungen@csihamburg.de
Workshop “Basic principles of immunology” 20 April 2016
| Member | 150 EUR |
| Non-Member | 180 EUR |
AGAH Annual Meeting 2016 „Exploratory drug development in immunotherapy“, 21 to 22 April 2016 (early bird until January 31, 2016)
| early bird | regular | |
| Member* | 300 EUR | 350 EUR |
| Non-Member | 380 EUR | 450 EUR |
| Junior Scientists (under age 30) | 150 EUR | 250 EUR |
| Day Ticket | 250 EUR | |
| Conference-Networking-Dinner | 50 EUR | 50 EUR |
Englisch
K. Breithaupt-Grögler, C. Coch, K. Erb-Zohar, S. Klammt, J. Rengelshausen, B. Schug, H. Sourgens, J. Täubel
Workshop: Basic principles of immunology – a training course
Chairs: C. Coch, M. Coenen
13:00 – 14:30
The innate immune system (pathogen-associated molecular patterns (PAMPs), phagocytes, etc.)
W. Barchet, Bonn
14:30 – 15:00
Break
15:00 – 16:30
The adaptive immune system (antibodies, T cells, etc.)
D. Wohlleber, München
16:30 – 17:00
Break
17:00 – 18:00
The immune system as a therapeutic target / tool – examples from rheumatology
T. Dörner, Berlin
18:30
Get together
Session 2: Drug-induced liver injury
Chairs: S. Plassmann, Munich (Germany); G. Wensing, Wuppertal (Germany)
19:00
AGAH General Assembly (Mitgliederversammlung)
08:45
Welcome and opening remarks
H. Sourgens, München
09:00 – 09:45
Immunotherapy – a growing field
D. Wolf, Bonn
Session 1: Suppressing mechanisms in immunotherapy
Chairs: H. Sourgens, D. Wolf
09:45 – 10:15
Beyond aspirin – new anti-inflammatory therapy for atherosclerosis
S. Zimmer, Bonn
10:15 – 10:45
Novel immune targets for monoclonal antibodies
C.Burkhart, Novartis
10:45 – 11:15
Induction of transplantation tolerance
B. Sawitzki, Berlin
11:15 – 11:45
Break
Session 2: Modulating mechanisms in immunotherapy
Chairs: J. Taeubel, H. Stauss
11:45 – 12:15
Modern immune and gene therapy of immunodeficiencies
M. Witzel, München
12:15 – 12:45
All is well that ends well – Fc part and design of immunoglobulins
I. Schwab, Erlangen
12:45 – 13:15
Designing the killer – CAR T cells in the treatment of tumour
H. Stauss, London
13:15 – 14:15
Break
Session 3: Activating mechanisms in immunotherapy
Chairs: J. Rengelshausen, C. Coch
14:15 – 14:45
Activation of the innate immune receptor RIG-I as novel target in the treatment of tumours and infectious diseases
C. Coch, Bonn
14:45 – 15:15
Inhibit the inhibitor – immune-checkpoint inhibitors in the treatment of tumors
A. Letsch, Berlin
15:15 – 15:45
Dose finding and patient selection in the development of immunotherapies: the case of immune-checkpoint inhibitors
J. Theis, Frankenforst
15:45 – 16:15
Break
Session 4: Immunotoxicity / Immunogenicity
Chairs: C. Meisel, K. Erb-Zohar
16:15 – 16:45
How to monitor immunotoxicity in novel immunological therapies?
C. Meisel, Berlin
16:45 – 17:15
How to monitor immunogenicity in novel immunological therapies?
A. Kromminga, Hamburg
19:30
Conference Dinner
Session 5: Early trials with vaccines
Chairs: B. Ziegele, B. Schug
09:00 – 09:30
Design and specific aspects of early clinical trials with novel vaccines
S.Yuansheng, Langen
09:30 – 10:00
Tumor vaccines – where do we come from? Where do we go?
F. A. Ossendorp, Leiden
10:00 – 10:30
Experience of vaccine development against ebola virus
C. Dahlke, Hamburg
10:30 – 11:00
Break
Session 6: Challenges in immunotherapy – what did we learn?
Chairs: H. Sourgens, K. Breithaupt
11:00 – 11:30
C5 inhibition and the associated recommended vaccine prophylaxis
J. Täubel, London
11:30 – 12:00
After the storm: the return of the CD28 superagonist TGN1412/TAB08 to clinical development.
T. Hünig, Würzburg
12:00 – 12:30
Has MABEL kept the promise? – 10 years of experience
B. Klug, Langen
12:30 – 13:00
Round table discussion
13:00
Concluding remarks
B. Schug
13:15
Farewell lunch
- Prof. Dr. Winfried Barchet
Universitätsklinikum Bonn - Dr. Kerstin Breithaupt-Grögler
-kbr- clinical pharmacology services, Frankfurt a.M. - Dr. Christian Burkhart
Novartis Pharma AG, Basel - Dr. Christoph Coch
Universitätsklinikum Bonn - Dr. Martin Coenen
Universitätsklinikum Bonn - Dr. Christine Dahlke
Universitätsklinikum Hamburg-Eppendorf - Prof. Dr. Thomas Dörner
Charité Berlin - Dr. Katharina Erb-Zohar
clinphase®, Hanau - Prof. Dr. Thomas Hünig
Universität Würzburg - Prof. Dr. Arno Kromminga
IPM Biotech GmbH, Hamburg - Dr. Bettina Klug
Paul-Ehrlich-Institut, Langen - PD Dr. Anne Letsch
Charité Berlin - Dr. Christian Meisel
Labor Berlin – Charité Vivantes GmbH, Berlin - Prof. Dr. Ferry A. Ossendorp
Leiden Univercity Medical Center, &Leiden NL - Dr. Jens Rengelshausen
Grünenthal GmbH - Prof. Dr. Birgit Sawitzki
Charité Berlin - Ms Inessa Schwab
Universität Erlangen-Lehrstuhl Genetik - Dr. Barbara Schug
SocraTec R&D GmbH, Oberursel - Prof. Dr. Hildegard Sourgens
Consultant, München - Prof. Dr. Hans Stauss
University College London - Dr. Jörg Täubel
Richmond Pharmacology Limited, London - Prof. Dr. Jochen Theis
InHeCon – Biotechnology , Bergisch-Gladbach - Dr. Maximilian Witzel
Kinderklinik und Kinderpoliklinik der LMU München - Dr. Dirk Wohlleber
Institut für Molekulare Immunologie und Experimentelle Onkologie, München - Prof. Dr. Dominik Wolf
Universitätsklinikum Bonn - Dr. Sun Yuansheng
Paul-Ehrlich-Institut, Langen - Ms Bettina Ziegele
Paul-Ehrlich-Institut, Langen - Dr. Sebastian Zimmer
Universitätsklinikum Bonn
Has MABEL kept the promise? Bettina Klug
Experience of vaccine development against Ebola virus Christine Dahlke
Induction of tolerance to allogeneic transplants – from preclinical models to clinical translation Birgit Sawitzki
21. April 2016 - 22. April 2016
25th AGAH Annual Meeting 2016
Annual Meeting 2016
Berlin
Deutschland